Neurosoft Bioelectronics raises USD 7.5M Seed round for brain-computer interfaces

Swiss neurotechnology company Neurosoft Bioelectronics has closed a USD 7.5 million oversubscribed Seed financing round to accelerate the development of its minimally invasive brain-computer interface (BCI) platform and expand clinical trials in the United States and Europe.

Neurosoft Bioelectronics is developing soft and stretchable neural interfaces designed to access the full cortex without penetrating brain tissue. According to the company, its electrodes are up to 1,000 times more compliant than those used in other flexible neural interfaces and can cover up to 30 times more cortical surface than current state-of-the-art BCIs, while requiring only a minimally invasive procedure.

The medtech company, a Venture Kick funding recipient, Venture Leaders alumnus, and ranked among the Top100 Swiss Startups, has now closed a USD 7.5 million oversubscribed seed financing round to accelerate clinical development and expand trials across the United States and Europe. The round was led by Skybound Venture Capital, with participation from Protocol Labs, IAG Capital Partners, and Connecticut Innovations, among others. With this latest financing, Neurosoft has raised more than USD 20 million to date.

Neurosoft has already tested its technology in 10 patients through ongoing clinical trials at UTHealth Houston and UMC Utrecht, including a 64-channel soft and stretchable brain interface study for epilepsy surgery guidance.

The funding will support the company’s next milestones, including minimally invasive deployment in human patients and the commercialization of its first brain interface product in the US.


Neurosoft Bioelectronics co-founders: CTO Ludovic Serex, CEO Nicolas Vachicouras, and CSO Florian Fallegger